- This event has passed.
Molecular Glues in Drug Discovery: Solutions that Stick for the Undruggable
October 5, 2022 @ 11:00 am - 12:00 pm PDT
Free
- Philip Chamberlain, Co-Founder, President, and CEO of Neomorph; Dr. Benjamin Ebert, Chair, Medical Oncology, Dana-Farber Cancer Institute; Janet Sasso, Information Scientist at CAS
- Sponsored by ACS Webinars and CAS
- 11am-Noon, Online via Zoom, Free, Registration required
Molecular glues have emerged as one of the promising approaches for drug discovery to treat a wide range of diseases such as cancer, inflammatory and immune diseases, and infections. Currently, conventional small molecule inhibitors can only target a small portion of disease-causing proteins, leaving the majority as undruggable. However, protein degradation utilizing small molecule glues is able to recruit non-druggable proteins for rapid destruction.
Join Philip Chamberlain the Co-Founder, President, and CEO of Neomorph, Dr. Benjamin Ebert, the Chair of Medical Oncology of the Dana-Farber Cancer Institute, and Janet Sasso, Information Scientist at CAS as they discuss a landscape view of the research and drug discovery efforts for molecular glues, the latest techniques for molecular glue drug discovery, and their application in the treatment of diseases.
This ACS Webinar is moderated by Angela Zhou, Information Scientist at CAS and is co-produced by CAS, a division of the American Chemical Society.
What You Will Learn
- Landscape views of molecular glue research, drug discovery, and therapeutic potential
- The latest molecular glue drug discovery efforts
- Application of molecular glues for disease treatment
Webinar Details
- Wednesday, October 5, 2022 @ 2-3pm ET
- Free to Register with ACS ID
- Slides will be available to download on the day of the webinar
Additional Resources
- Molecular Glues and Induced Proximity – Article by Janet Sasso of CAS
- Molecular Glues are Beginning to Stick – Article by Gina Vitale of C&EN